AddedRisk Factors
We and our directors and officers may be subject to lawsuits relating to the Merger.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
Litigation is very common in connection with the sale of public companies, regardless of whether the claims have any merit. One of the conditions to consummating the Merger is that no order enjoining, prohibiting or otherwise making illegal the consummation of the Merger shall have been issued by any governmental authority, including a court. Consequently, if any lawsuit challenging the Merger is successful in obtaining an order preventing the consummation of the Merger, that order may delay or prevent the Merger from being completed. While we will evaluate and defend against any lawsuits, the time and costs of defending against litigation relating to the Merger may adversely affect our business.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
Provisions of the Merger Agreement may deter alternative business combinations and could negatively impact our stock price if the Merger Agreement is terminated in certain circumstances.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
The Merger Agreement prohibits us from soliciting, initiating, knowingly facilitating or knowingly encouraging any inquiries, proposals or offers that would be reasonably expected to lead to certain alternative takeover proposals with any third party, and from taking other similar actions, subject to exceptions set forth in the Merger Agreement. The Merger Agreement also provides for the payment by us of a termination fee of $525.0 million if the Merger Agreement is terminated in certain circumstances in connection with a competing third-party acquisition proposal. These provisions limit our ability to pursue offers from third parties that could result in greater value to our stockholders. The obligation to pay the termination fee may also discourage a third party from pursuing an alternative acquisition proposal. If the Merger Agreement is terminated and we determine to seek another business combination, we cannot assure our stockholders that we will be able to negotiate a transaction with another company on terms comparable to the terms of the Merger Agreement, or that we will avoid incurrence of any fees associated with the termination of the Merger Agreement. In the event the Merger Agreement is terminated, our stock price may decline.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedRisk Factors
long term international revenue growth. We have in the past experienced turnover with some of our distributors that has adversely affected sales in the countries in which those distributors operate. Similar occurrences could happen in the future.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
your investment in our common stock since you might be unable to sell your shares at or above the price you paid for such shares. Factors that could cause fluctuations in the market price of our common stock include the following:
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
•requiring supermajority stockholder voting to effect certain amendments to our restated certificate of incorporation and second amended and restated bylaws;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
•dividing our board of directors into three classes so that only one third of our directors will be up for election in any given year; and
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
partners. To the extent that such disruptions occur, our customers and partners may lose confidence in our company and we may lose business or brand reputation, resulting in a material and adverse effect on our business, financial condition, results of operations or cash flows.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedRisk Factors
Failure to comply with regulatory requirements or the discovery of previously unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory approvals or clearances, seizures or recalls of products (with the attendant expenses and adverse competitive impact), the banning of a particular device, an order to replace or refund the cost of any device previously manufactured or distributed, operating restrictions and criminal prosecution, as well as decreased sales as a result of negative publicity and product liability claims, all of which could have a material adverse effect on our business, results of operation, financial condition or cash flows.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the information we rely upon to run our businesses were to be found to be inaccurate or unreliable, if we fail to maintain or protect our information technology systems and data integrity effectively, if we fail to develop and implement new or upgraded systems to meet our business needs in a timely manner, or if we fail to anticipate, plan for or manage significant disruptions to these systems, our competitive position could be harmed, we could have operational disruptions, we could lose existing customers, have difficulty preventing, detecting, and controlling fraud, have disputes with customers, specialist physicians and other healthcare providers, have regulatory sanctions or penalties imposed or other legal problems, incur increased operating and administrative expenses, lose revenues as a result of a data privacy breach or theft of intellectual property or suffer other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition or cash flows.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries where such third parties have registered such trademarks or obtained such common law rights.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, certain unique macroeconomic and geopolitical factors, including those as a result armed conflict in various parts of the Russian invasion of Ukraine or conditions in the Middle East as a result of the Israel-Hamas conflict, world, may cause instability and volatility in the global financial markets and disruptions within the healthcare industry that may negatively impact our business.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Accordingly, although we have multiple contracts with many major GPOs and IDNs, the members of such groups may choose to purchase from our competitors due to the price or quality offered by such competitors, which could result in a decline in our sales and profitability.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
These broad market and industry factors may harm the market price of our common stock, regardless of our operating performance, and could cause you to lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you paid for such shares.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are expanding and renovating our existing facilities around the world but particularly world, including in Alameda, Alameda and Roseville California, and establishing new manufacturing facilities in Costa Rica, driven by our need to expand the space available for our product manufacturing and product development and test testing capacities, as well as our need for additional information technology and office space.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
If key personnel were to leave Penumbra, either to join our competitors or otherwise, we may not be able to attract and retain equally qualified personnel to replace them, which could harm our ability to develop and successfully grow our business.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We currently produce substantially all of our products at our manufacturing facilities in Alameda and Roseville, California, and, while we have entered into agreements to acquire property in Costa Rica and construct a manufacturing facility and warehouse for our products, we can give no assurance that these facilities will be adequate for our future needs.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with components and raw materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by patients, hospitals, healthcare providers or others purchasing or using our products, even if our products were not the actual cause of such injury or death.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Furthermore, other parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen, and severe adverse events.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
On January 14, 2026, we entered into the Merger Agreement with Boston Scientific Corporation and Merger Sub, pursuant to which Boston Scientific Corporation has agreed to acquire us in the Merger at an enterprise value of approximately $14.5 billion. Under the terms of the Merger Agreement, which has been approved by the board of directors of each of the Company and Boston Scientific Corporation, the transaction values each share of our common stock at $374 per share, with our stockholders having the right to elect, for each share of our common stock held by them, to receive $374 in cash or 3.8721 shares of Boston Scientific Corporation’s common stock (valued at $374 based on the volume weighted average price of Boston Scientific Corporation’s common stock over the 10 trading days ending January 13, 2026), subject to proration, so that the total
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, President Trump signed the One Big Beautiful Bill Act (“OBBBA”) into law, which extends and modifies various domestic and international business tax framework originally enacted under the Tax Cuts and Jobs Act (“TCJA”). The legislation includes multiple effective dates, with certain provisions taking effect in 2025 and others through 2027. We evaluated the OBBBA and included its impact within our consolidated financial statements. We will continue to evaluate the full impact of these legislative changes as additional supplemental guidance becomes available.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedMD&A
The fair value of in-process research and development asset (“IPR&D”) projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project is completed, at which point the intangible asset will be accounted for as a finite-lived intangible asset. If a project is abandoned prior to completion, the carrying value of the IPR&D asset is written off. IPR&D acquired in an asset acquisition for use in research and development activities with no alternative future use are expensed in the consolidated statements of operations on the acquisition date. Accounting for acquisitions of IPR&D requires the Company to make certain judgements to determine if the transaction should be accounted for as an asset acquisition or a business combination, as well as assess if the IPR&D project has alternative future use in research and development activities.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
Finite-lived intangible assets are amortized over the estimated economic useful lives of the assets, which is the period during which expected cash flows support the fair value of such intangible assets. We review finite-lived intangible assets and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We also periodically review the useful lives assigned to our intangible assets to ensure that our initial estimates do not exceed any revised estimated periods from which we expect to realize cash flows from the underlying intangible asset. If a change were to occur in any of the above-mentioned factors or estimates, the likelihood of a material change in our reported results would increase.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When such an event occurs, management determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the related asset group’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
Our impairment tests require the use of assumptions and estimates, such as industry economic factors and the profitability of future business strategies. To estimate undiscounted future cash flows of long-lived assets, we may apply a probability-weighted approach that incorporates different assumptions and potential outcomes related to the underlying long-lived assets. The evaluation is performed at the lowest level for which separately identifiable cash flows exist. To estimate the fair value of these assets, we generally use a discounted cash flow under the income approach, which requires significant judgment, including the timing and weighting placed on potential outcomes for the asset group.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedMD&A
The following table sets forth, for the periods indicated, our beginning balance of cash and cash equivalents, net cash flows provided by (used in) operating, investing and financing activities and our ending balance of cash and cash equivalents:Year Ended December 31, 2025 2024 2023 2022 (in thousands) Cash and cash equivalents at beginning of year $ 324,404 $ 167,486 $ 69,858 $ 59,379 Net cash provided by operating activities 238,663 168,481 97,333 Net cash (used in) provided by investing activities (404,590) 77,624 (16,076) Net cash provided by (used in) operating activities 168,481 97,333 (55,661) Net cash provided by (used in) investing activities 77,624 (16,076) 54,790 Net cash (used in) provided by financing activities 26,532 (87,006) 16,203 11,622 Effect of foreign exchange rate changes on cash and cash equivalents 1,888 (2,181) 168 Cash and cash equivalents at end of year 186,897 324,404 167,486 69,858
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Gross This compares to gross margin was of 63.2% in 2024, including a $7.3 million reduction in revenue resulting from the Italian government’s payback provision, which requires medical device companies to make payments to the Italian government for any deficit created by Italian budget overspend on medical devices, and included a one-time $33.4 million inventory charge to cost of revenue in connection with the impairment of our Immersive Healthcare immersive healthcare asset group (refer to Note “4.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by used in investing activities was $54.8 $404.6 million in 2022 2025 and primarily consisted of purchases of marketable investments, net of proceeds from maturities and sales of marketable investments investments, of $74.1 million, partially offset by $340.9 million and capital expenditures of $19.3 million. $63.7 million primarily driven by investments related to the construction of our Costa Rica manufacturing facility.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The Company incurred a $33.4 million charge to cost of revenue for the write-down of Immersive Healthcare immersive healthcare inventory to net realizable value, an impairment charge to long-lived assets consisting of $58.9 million in finite-lived intangible assets and $18.0 million in property and equipment, and severance and other associated costs of $5.0 million included in research and development and sales, general and administrative within the consolidated statement of operations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities was $16.2 $26.5 million in 2023 2025 and primarily consisted of proceeds from the issuance of common stock under our employee stock purchase plan of $14.9 $16.4 million and proceeds from exercises of stock options of $5.5 $15.4 million, partially offset by payments of employee taxes related to vested restricted stock units of $2.5 million and payments towards finance leases obligations of $2.5 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash (used in) provided by (used in) investing activities primarily relates primarily to proceeds from maturities of marketable investments, partially offset by purchases of marketable and non-marketable investments, capital expenditures, and payments in connection with asset acquisitions. acquisitions, partially offset by sales of marketable investments and proceeds from maturities of marketable investments.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
This was partially offset by an increase in accrued expenses and other non-current liabilities of $6.2 $12.9 million primarily as a result of the growth in our business activities, and an increase in accounts payable of $1.1 million, and proceeds of $0.5 million received related to lease incentives from operating leases. $3.1 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Our change in effective tax rate was primarily attributable to an increase in excess tax benefits from stock-based compensation and substantial tax benefits recorded from releasing the valuation allowance against federal research and development credits and partial California DTAs in 2023. compensation.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Revenue from our global thrombectomy embolization and access products increased $138.1 $76.6 million, or 20.4%, 20.2%, to $815.5 $455.7 million in 2024, the year ended December 31, 2025, from $677.3 $379.1 million in 2023. the year ended December 31, 2024.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Exit of Immersive Healthcare BusinessYear Ended December 31, Change 2025 2024 2023 $ % (in thousands, except for percentages) Cost of revenue $ $ 33,362 $ $ 33,362 100.0% (33,362) (100.0)% Impairment charge 76,945 — 76,945 100.0% (76,945) (100.0)% Severance and other associated costs 4,971 — 4,971 100.0% (4,971) (100.0)% Impact of Immersive Healthcare Business Exit $ $ 115,278 $ $ 115,278 100.0% (115,278) (100.0)% Exit impact as a percentage of revenue —% 9.6 % —%
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The change in operating assets and liabilities includes an increase in inventories of $67.7 $26.5 million to support our revenue growth, an increase in accounts receivable of $19.5 million, and an increase in prepaid expenses and other current and non-current assets of $18.9 million, and an increase in accounts receivable of $0.3 $12.7 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by operating activities was $97.3 $238.7 million in 2023 2025 and consisted of net income of $91.0 $177.7 million and non-cash items of $103.7 million offset by net changes in operating assets and liabilities of $79.1 million offset by non-cash items of $85.5 $42.7 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new